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Introduction
　Chronic obstructive pulmonary disease （COPD） is an inammatory lung disease related 
to the long-term inhalation of noxious substances, including tobacco smoke.  COPD is 
characterized by progressive airow obstruction, which may not return to normal on respira-
tory function tests, exertional dyspnea, and chronic cough / sputum1）.  In 2000, COPD was 
reported to be the fourth most common cause of mortality worldwide2）.
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Abstract : Recent studies have shown that chronic obstructive pulmonary dis-
ease （COPD） causes various extrapulmonary comorbidities.  In addition, car-
diovascular disease, the pathogenesis of which involves atherosclerosis, has been 
emphasized as a cause of mortality in patients with COPD.  In the present 
study, we investigated the presence of classical risk factors for atherosclerosis 
in 183 patients with COPD.  The prevalence of comorbidities （hypertension, 
diabetes mellitus ［DM］, and dyslipidemia） was investigated and compared 
with that in a general population.  In patients with COPD, the prevalence of 
hypertension, DM, and dyslipidemia was 43.2％, 15.8％, and 25.7％, respectively, 
with the prevalence of DM and dyslipidemia significantly higher in patients 
than in the general population.  Furthermore, there were signicant differences 
in the prevalence of the three disorders in patients with COPD.  For example, 
the prevalence of hypertension was significantly higher than that of diabetes 
mellitus in patients aged 60-69 years and higher than the prevalence of DM 
and dyslipidemia in patients aged 70 years.  Regardless of age, hypertension 
was noted in the greatest number of patients.  In conclusion, a high propor-
tion of patients with COPD were found to have the classical risk factors for 
atherosclerosis.  In particular, the prevalence of DM and dyslipidemia was 
signicantly higher in COPD patients than in the general population.
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　Recent studies have shown that COPD causes various extrapulmonary comorbidities. 
Thus, it is important to recognize COPD not only as a respiratory disease, but also as a 
systemic disease3）.  Cardiovascular disease, the pathogenesis of which involves atherosclerosis, 
has been reported to be responsible for approximately 30％ of deaths in patients with 
COPD 4, 5）.  Furthermore, hypertension, diabetes mellitus （DM）, and dyslipidemia, clas-
sical risk factors for atherosclerosis, have been detected in a high proportion of COPD 
patients6-8).  However, few studies have reported on comorbidities of COPD in Japan.  In 
the present study, we focused on hypertension, DM, and dyslipidemia as comorbidities of 
COPD and determined their prevalence in patients with COPD compared with that in a 
general population.
Methods
Subjects
　The COPD group in the present retrospective study consisted of 183 patients who had 
periodically consulted the outpatient clinic of the Division of Respiratory and Allergy, 
Department of Internal Medicine, Showa University School of Medicine, or the Depart-
ment of Internal Medicine, Showa University Toyosu Hospital for the treatment of COPD 
between April 2008 and March 2009 （165 males, 18 females ; mean age 74.2 ± 8.1 years 
［range 52-93 years］; Table 1）.  The general population used for comparisons was made 
up of people over 50 years of age who were selected based on data on hypertension, DM, 
and dyslipidemia from the National Health and Nutrition Survey （2006） published by the 
Ministry of Health, Labour and Welfare 9） （Table 2）.
Methodology
　Information was obtained regarding the patients’ age, gender, stage of COPD, and the 
Table 1.  Characteristics of patients with COPD
Number of patients 183
Male / Female, number 165 / 18
Mean age （SD）, years 74.2 （8.1）
Age-groups, number
 50-59ys   6
 60-69ys  51
 70ys- 126
Stage of COPD, number  （Age-groups : number）
 I 43 （50-59 : 0, 60-69 : 11, 70- : 32）
 II 78 （50-59 : 4, 60-69 : 24, 70- : 50）
 III 41 （50-59 : 2, 60-69 : 13, 70- : 26）
 IV 21 （50-59 : 0, 60-69 :  3, 70- : 18）
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presence or absence of comorbidities （hypertension, DM, and dyslipidemia）.  The number 
of COPD patients with these comorbidities as a proportion of all patients was determined, 
as was the prevalence of the comorbidities with respect to age and stage of disease.  The 
prevalence of hypertension, DM, and dyslipidemia was compared between the COPD 
patients and the general population.  A diagnosis of COPD was made with stage assessment 
according to the Guidelines for the Diagnosis and Treatment of COPD （Chronic Obstruc-
tive Pulmonary Disease） issued by the Japanese Respiratory Society10）.  Patients were 
determined to have hypertension, DM, or dyslipidemia if they were receiving drug therapy 
for that disease.  Similarly, in the general population, any result reported as “person taking 
a drug” in the National Health and Nutrition Survey was taken as an indication that that 
person had the disease.
Statistical analysis
　When comparing the prevalence of hypertension, DM, and dyslipidemia between COPD 
patients and the general population, data obtained from the National Health and Nutrition 
Survey for the “general population” in the present study were adjusted for age and gender 
in the COPD group using direct standardization methods.  The Chi-squared test was used to 
compare percentages.  P＜ 0.05 was considered signicant.
Results
　Significant differences were noted in the prevalence of three comorbidities in COPD 
patients : 79 patients （43.2％） had hypertension, 47 （25.7％） had dyslipidemia, and 29 
（15.8％） had DM （Table 3）.  Overall, 105 patients （57.4％） were found to have at least 
one of the three comorbidities.
　The prevalence of hypertension, DM, and dyslipidemia in patients aged 50-59 years was 
Table 2.  Raw data of characteristics of the control group 
（National Health and Nutrition Survey 2006）
Age-groups, y 50-59 60-69 70- total
Object of survey
male / female male / female male / female
Hypertension object（n） 363 / 544 411 / 561 504 / 631 3014
prevalence（n） 76 / 78 130 / 170 232 / 305 991
prevalence（％） 20.9 / 14.3 31.6 / 30.3 46.0 / 48.3 32.9
Dyslipidemia object（n） 351 / 525 390 / 527 474 / 582 2849
prevalence（n） 31 / 68 38 / 101 49 / 140 427
prevalence（％） 8.8 / 13.0 9.7 / 19.2 10.3 / 24.1 15.0
Diabetes object（n） 350 / 525 389 / 523 472 / 580 2839
prevalence（n）  17 / 12 28 / 36 56 / 49 198
prevalence（％） 4.9 / 2.3 7.2 / 6.9 11.9 / 8.4 7.0
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33.3％, 16.6％, and 16.6％, respectively ; in the 60-69 years age group, the prevalence of the 
three comorbidities was 37.3％, 19.6％, and 31.4％, respectively ; whereas in patients 70 years 
of age, the prevalence was 46.0％, 14.3％, and 23.8％, respectively.  There was a signicant 
difference between the prevalence of hypertension and DM in subjects aged 60-69 years. 
Similarly, significant differences were found between the prevalence of hypertension and 
dyslipidemia / DM in patients aged 70 years.  The proportion of patients with hypertension 
was the highest, regardless of age （Table 4）.  There were no signicant differences in the 
prevalence of these comorbidities in patients with different stages of the disease （Table 5）.
　To enable comparisons with COPD patients, a “general population” was created by 
age and gender adjustment of results from the National Health and Nutrition Survey. 
Table 3.  Prevalence of comorbidities among patients with COPD （n＝ 183）
Comorbidity Number  ％
Hypertension 79 43.2
Dyslipidemia 47 25.7
Diabetes mellitus 29 15.8
＊ : P＜ 0.05, ＊＊ : P＜ 0.001
＊＊
＊＊
＊
Table 4.  Prevalence of comorbidities among patients with COPD according to each age group
Age-groups Comorbidity, ％ （number）
Hypertension Dyslipidemia Diabetes mellitus
50-59 33.3 （2） 16.6 （1） 16.6 （1）
60-69 37.3 （19） 31.4 （16） 19.6 （10）
70- 46.0 （58） 23.8 （30） 14.3 （18）
＊ : p＜ 0.05, ＊＊ : P＜ 0.001
＊
＊＊
＊＊
Table 5.  Prevalence of comorbidities among patients with COPD according to each COPD stage
COPD stage Comorbidity, ％ （number）
Hypertension Dyslipidemia Diabetes mellitus
I n＝ 43 46.5 （20） 34.9 （15） 16.3 （7）
II n＝ 78 46.2 （36） 25.6 （20） 17.9 （14）
III n＝ 41 39.0 （16） 17.1 （7） 14.6 （6）
IV n＝ 21 33.3 （7） 23.8 （5） 9.5 （2）
n.s. : not signicant
n.s.
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Following adjustment, 1242 of 3014 people （41.2％） of the general population were found 
to have hypertension, 321 of 2849 （11.3％） had dyslipidemia, and 287 of 2839 （10.1％） had 
DM （Table 6）.  Comparison of the prevalence of these conditions between the general 
population and the COPD patients revealed that the prevalence of DM and dyslipidemia 
was signicantly higher in patients with COPD.  There was no signicant difference in the 
prevalence of hypertension between the two groups （Fig. 1）.
Table 6.  Adjusted data of characteristics of the control group
Age-groups, y 50-59 60-69 70- total
Object of survey
male / female male / female male / female
Hypertension object（n） 38 / 97 349 / 578 891 / 1061 3014
prevalence（n） 8 / 14 110 / 178 409 / 523 1242
prevalence（％） 21.0 / 14.4 31.5 / 30.8 45.9 / 49.3 41.2
Dyslipidemia object（n） 37 / 91 331 / 545 847 / 998 2849
prevalence（n） 4 / 6 36 / 54 97 / 124 321
prevalence（％） 10.8 / 6.6 10.9 / 9.9 11.5 / 12.4 11.3
Diabetes object（n） 37 / 90 330 / 543 844 / 995 2839
prevalence（n） 2 / 3 23 / 50 98 / 111 287
prevalence（％） 5.4 / 3.3 7.0 / 9.2 11.6 / 11.2 10.1
Fig. 1.  Comparison of prevalence of comorbidities between COPD and control groups
The prevalence of hypertension was not significantly different between COPD and control 
groups. The prevalence of dyslipidemia and diabetes mellitus in the COPD group was signi-
cantly higher than in the control group.
H / T : hypertension, DL : dyslipidemia, DM : diabetes mellitus, n.s. : not signicant, ＊: p＜ 0.001, 
＊＊: p＜ 0.05
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Discussion
　COPD has been reported to cause various extrapulmonary comorbidities and the impor-
tance of recognizing COPD as a systemic disease has been emphasized3）.  As a comorbidity 
of COPD, cardiovascular disease in particular has been investigated as a cause of mortality 
in patients with COPD4, 11, 12）.
　Of the three comorbidities evaluated in the present study, namely hypertension, DM, and 
dyslipidemia, all of which are classical risk factors for atherosclerosis, hypertension was the 
most prevalent in patients with COPD, as reported previously 6-8).  The second most frequent 
comorbidity was dyslipidemia, followed by DM.  The prevalence of DM and dyslipidemia 
was signicantly higher in COPD patients than in the general population.  The prevalence 
of hypertension increased with age, showing signicant differences compared with the other 
comorbidities.  However, there was no signicant difference in the prevalence of hyperten-
sion between COPD patients and the general population, suggesting the inuence of age.
　Recent studies have revealed the presence of systemic inflammation in patients with 
COPD 13-15).  Because various chronic comorbidities related to systemic inflammation have 
been observed, “chronic systemic inammatory syndrome” has been introduced as a disease 
entity16）.  Therefore, in the present study, it may be that COPD-specic systemic inamma-
tion contributed to a significant increase in impaired glucose / lipid metabolism in patients 
with COPD.  However, this requires further investigation, with the precise etiology and 
mechanisms underlying the dyslipidemia and DM in COPD patients yet to be determined.
　The pathogenesis of cardiovascular disease in the presence of COPD is unclear.  A 
recent study reported that inflammation was involved in the onset and deterioration of 
atherosclerosis, and so atherosclerosis has been recognized as an inammatory disease 17）, as 
has COPD.  In addition, many studies have suggested that systemic inammation in COPD 
patients contributes to the development of cardiovascular disease18-25）.  Taking these ndings 
into consideration, the development of cardiovascular disease in the presence of COPD may 
be due to an additive / synergistic effect of systemic inammation and classical risk factors 
for atherosclerosis.
　In the present study, approximately 60％ of COPD patients had classical risk factors for 
atherosclerosis.  In particular, the prevalence of DM and dyslipidemia was signicantly higher 
in COPD patients than in the general population.  Thus, controlling atherosclerosis in COPD 
patients may prevent the development of cardiovascular disease, subsequently improving the 
prognosis for these patients.  Therefore, in the clinical management of COPD, screening for 
and the treatment of any classical risk factors for atherosclerosis may prove to be important, 
recognizing COPD as a systemic disorder.
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